Viyash has ten manufacturing facilities in India with a combined capacity of 2000 KL as well as one formulation facility in the US, and is now one of India’s leading mid-tier integrated API and formulation players
Branded and unbranded versions of the first-ever interchangeable biosimilar in the U.S. provide more affordable options for the millions of Americans living with diabetes
Two out of three people under the age of 40 are at risk of prediabetes
BRIDGE-1 Comprehensive care programme for Type 1 diabetes and to train 400 physicians and benefit over 1000 children
Forty-two per cent Indian patients with Coronary Artery Disease (CAD) or Peripheral Artery Disease (PAD) described “confusion about what I was supposed to do next” as an important barrier to early and accurate diagnosis
The initiative will engage adolescents and youth of India in decisions about their reproductive health
The company performed particularly well in operational eco-efficiency, environmental and social reporting
The company expects to begin shipping this product before the end of its fiscal first quarter, ending December 31, 2021
The ground-breaking project, led by Genomics England and NHS England, was established in 2013 to sequence 100,000 whole genomes from NHS patients and their families
The centre has an initial capacity of 500 FTEs
Subscribe To Our Newsletter & Stay Updated
